Evidence map›Paper›PMID 30941623›Full record

ArticleJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology2019

Resveratrol (3, 5, 4'-Trihydroxy-trans-Stilbene) Attenuates a Mouse Model of Multiple Sclerosis by Altering the miR-124/Sphingosine Kinase 1 Axis in Encephalitogenic T Cells in the Brain.

K Alexa Orr Gandy, Jiajia Zhang, Prakash Nagarkatti, Mitzi Nagarkatti

Open access · greenAbstract read
In one paragraph

Article in Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 57 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

K Alexa Orr GandyDepartment of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, SC, 29209, USA.
Jiajia ZhangEpidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.
Prakash NagarkattiDepartment of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, SC, 29209, USA.
Mitzi NagarkattiDepartment of Pathology, Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, SC, 29209, USA. Mitzi.Nagarkatti@uscmed.sc.edu.
University of South Carolina · US

Funding

Targeting early ceramide elevation in pre-symptomatic eczemaP20GM103641 · NIGMS · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI ENOS, REILLY, NAGARKATTI, PRAKASH S · 2012 to 2023
$20.7M
Use of Resveratrol to treat experimental multiple sclerosisP01AT003961 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI HOFSETH, LORNE J · 2007 to 2018
$14.2M
Epigenetic Mechanisms of T Cell Dysregulation in PTSDR01AI129788 · NIAID · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, MITZI · 2017 to 2021
$2.4M
Role of natural indoles in experimental autoimmune encephalomyelitisR01AT006888 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, MITZI · 2011 to 2015
$2.0M
AhR ligands in epigenetic dysregulation of T cellsR01AI123947 · NIAID · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, MITZI, NAGARKATTI, PRAKASH S · 2017 to 2021
$1.8M
Immunopathological basis of PTSDR01MH094755 · NIMH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI NAGARKATTI, PRAKASH S · 2011 to 2015
$1.7M
MicroRNA regulation of EAE by resveratrolF32AT008539 · NCCIH · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI GANDY, K ALEXA · 2014 to 2016
$177k
NCCIH NIH HHS F32 AT008539NCCIH NIH HHS P01 AT003961NCCIH NIH HHS R01 AT006888NIAID NIH HHS R01 AI123947NIAID NIH HHS R01 AI129788NIGMS NIH HHS P20 GM103641NIMH NIH HHS R01 MH094755
6 · The paper itself

Abstract

Resveratrol (3,5,4'-trihydroxy-trans-stilbene) (RES) is a naturally-derived phytoestrogen found in the skins of red grapes and berries and has potential as a novel and effective therapeutic agent. In the current study, we investigated the role of microRNA (miRNA) in RES-mediated attenuation of experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis. Administration of RES effectively decreased disease severity, including inflammation and central nervous system immune cell infiltration. miRNA microarray analysis revealed an altered miRNA profile in encephalitogenic CD4+ T cells from EAE mice exposed to RES treatment. Additionally, bioinformatics and in silico pathway analysis suggested the involvement of RES-induced miRNA in pathways and processes that regulated cellular proliferation. Additional studies confirmed that RES affected cell cycle progression and apoptosis in activated T cells, specifically in the brain. RES treatment significantly upregulated miR-124 during EAE, while suppressing associated target gene, sphingosine kinase 1 (SK1), and this too was specific to mononuclear cells in the brains of treated mice, as peripheral immune cells remained unaltered upon RES treatment. Collectively, these studies demonstrate that RES treatment leads to amelioration of EAE development through mechanism(s) potentially involving suppression of neuroinflammation via alteration of the miR-124/SK1 axis, thereby halting cell-cycle progression and promoting apoptosis in activated encephalitogenic T cells. Graphical Abstract Resveratrol alters the miR-124/sphingosine kinase 1 (SK1) axis in encephalitogenic T cells, promotes cell-cycle arrest and apoptosis, and decreases neuroinflammation in experiemental autoimmune encephalomyelitis (EAE).

Indexed as

AnimalsApoptosisBrainCD4-Positive T-LymphocytesCell CycleCell DivisionDrug Evaluation, PreclinicalEncephalomyelitis, Autoimmune, ExperimentalEnzyme InductionFemaleGene Expression RegulationGene OntologyLymphocyte ActivationMiceMice, Inbred C57BLMicrogliaMicroRNAsMirn124 microRNA, mouseNerve Tissue ProteinsPhosphotransferases (Alcohol Group Acceptor)ResveratrolSphingosine KinaseSphk1 protein, mouseCD4+ T cellsExperimental autoimmune encephalitis (EAE)microRNA 124 (miR-124)Multiple sclerosis (MS)Resveratrol (RES)Sphingosine kinase 1 (SK1)

Identifiers

PMID30941623
PMCPMC6900929
OpenAlexW2928939598

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.